Integra LifeSciences will release Q2 2025 financial results on July 31, followed by a conference call at 8:30 a.m. ET.
Quiver AI Summary
Integra LifeSciences Holdings Corporation announced that it will release its second quarter 2025 financial results on July 31, 2025, before the market opens. Following the release, the management team will host a conference call at 8:30 a.m. ET, with a live webcast accessible on the company's website. Participants are encouraged to register in advance for dial-in details. A replay of the call will be available online afterward. Integra LifeSciences is committed to improving patient outcomes through innovative treatments in surgical, neurologic, and regenerative care. For more information, visit the company’s website.
Potential Positives
- Integra LifeSciences will provide a timely update on their financial performance for the second quarter of 2025, indicating transparency and accountability to investors.
- The scheduled conference call demonstrates the company's commitment to engaging with stakeholders and providing insights into their operations and future outlook.
- The live webcast availability allows for broader access to the information presented, ensuring that both investors and interested parties can stay informed.
- The focus on innovation and improving patient outcomes reinforces Integra's position as a leader in the medical technology industry and its dedication to advancing healthcare solutions.
Potential Negatives
- None
FAQ
When will Integra LifeSciences release its Q2 2025 financial results?
Integra LifeSciences will release its Q2 2025 financial results on Thursday, July 31, 2025, prior to market open.
What time is the conference call for the Q2 earnings?
The conference call for the Q2 earnings will start at 8:30 a.m. ET on July 31, 2025.
How can I access the webcast of the conference call?
A live webcast of the conference call will be available on the Investors section of Integra's website at investor.integralife.com.
Is registration required to participate in the conference call?
Registration is not required, but it is recommended to join the call 10 minutes early for dial-in details.
Where can I find further information about Integra LifeSciences?
For the latest news and information, visit Integra LifeSciences' website at www.integralife.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IART Hedge Fund Activity
We have seen 96 institutional investors add shares of $IART stock to their portfolio, and 108 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RUBRIC CAPITAL MANAGEMENT LP added 2,025,331 shares (+77.4%) to their portfolio in Q1 2025, for an estimated $44,537,028
- INVESCO LTD. added 1,364,345 shares (+66.0%) to their portfolio in Q1 2025, for an estimated $30,001,946
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 794,865 shares (+inf%) to their portfolio in Q1 2025, for an estimated $17,479,081
- ASSENAGON ASSET MANAGEMENT S.A. removed 605,765 shares (-33.7%) from their portfolio in Q2 2025, for an estimated $7,432,736
- CAPITAL RESEARCH GLOBAL INVESTORS removed 574,817 shares (-41.0%) from their portfolio in Q1 2025, for an estimated $12,640,225
- MORGAN STANLEY removed 510,463 shares (-9.6%) from their portfolio in Q1 2025, for an estimated $11,225,081
- MILLENNIUM MANAGEMENT LLC added 397,029 shares (+1809.0%) to their portfolio in Q1 2025, for an estimated $8,730,667
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IART Analyst Ratings
Wall Street analysts have issued reports on $IART in the last several months. We have seen 3 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 05/09/2025
- JP Morgan issued a "Underweight" rating on 05/06/2025
- Argus Research issued a "Buy" rating on 03/31/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 02/26/2025
To track analyst ratings and price targets for $IART, check out Quiver Quantitative's $IART forecast page.
$IART Price Targets
Multiple analysts have issued price targets for $IART recently. We have seen 5 analysts offer price targets for $IART in the last 6 months, with a median target of $19.0.
Here are some recent targets:
- David Turkaly from JMP Securities set a target price of $25.0 on 05/09/2025
- Robbie Marcus from JP Morgan set a target price of $12.0 on 05/06/2025
- Vik Chopra from Wells Fargo set a target price of $13.0 on 05/06/2025
- Richard Newitter from Truist Securities set a target price of $19.0 on 04/11/2025
- David Turkaly from Citizens Capital Markets set a target price of $35.0 on 02/26/2025
Full Release
PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com . For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.
About Integra LifeSciences
At Integra LifeSciences, we are driven by our purpose of restoring patients’ lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit www.integralife.com .
Investor Relations:
Chris Ward
(609) 772-7736
[email protected]
Media Contact:
Laurene Isip
(609) 208-8121
[email protected]
